A new treatment approach is showing promise in potentially delaying the require for hormone therapy in some men diagnosed with prostate cancer, according to findings from a recent clinical study. The research, presented at the European Society for Medical Oncology (ESMO) Congress 2023, offers a potential alternative for men with early-stage prostate cancer who are closely monitored, a strategy known as active surveillance. This could significantly reduce the side effects associated with immediate hormone treatment, which can include fatigue, sexual dysfunction, and bone loss.
Prostate cancer is the most common cancer in men worldwide, with over 1.4 million new cases diagnosed globally in 2020, according to the World Health Organization. While many cases are gradual-growing and manageable with active surveillance, others require more aggressive intervention. Hormone therapy, which lowers testosterone levels, is a standard treatment for advanced prostate cancer and is often used in men with rapidly progressing disease. However, initiating hormone therapy too early can diminish quality of life and potentially lead to resistance over time.
Targeting the Tumor Microenvironment
The new treatment, developed by researchers at the University of Michigan Rogel Cancer Center, focuses on modifying the tumor microenvironment – the area surrounding the cancer cells – rather than directly targeting the cancer cells themselves. The approach involves using a drug called ONCOS-102, an investigational agent that aims to disrupt the support system that tumors rely on to grow and spread. Specifically, ONCOS-102 is designed to deplete cancer-associated fibroblasts (CAFs), cells that contribute to the tumor’s structure and protect it from the immune system.
The Phase 2 clinical trial, published in the Journal of Clinical Oncology, involved 46 patients with intermediate-risk prostate cancer who were undergoing active surveillance. Participants received ONCOS-102 injections directly into their tumors. The study found that a significant proportion of patients experienced a delay in the need for hormone therapy or other definitive treatments, such as radiation or surgery. After a median follow-up of 18 months, 88% of patients were still on active surveillance, avoiding the immediate side effects of more aggressive treatments.
How ONCOS-102 Works and Trial Results
“The idea is to change the environment around the cancer cells, making it less hospitable for them to grow,” explains Dr. Ganesh Palapattu, lead author of the study and a professor of urology at the University of Michigan. “By depleting the CAFs, we’re essentially cutting off the tumor’s support network.” The study also showed that ONCOS-102 was generally well-tolerated, with the most common side effects being mild injection-site reactions.
Researchers assessed the treatment’s effectiveness by monitoring prostate-specific antigen (PSA) levels, a marker often elevated in prostate cancer, and through repeat biopsies. The results indicated that ONCOS-102 led to a reduction in CAF density within the tumors and a stabilization of PSA levels in many patients. Importantly, the study also showed evidence of immune cell infiltration into the tumors, suggesting that the treatment may also enhance the body’s natural ability to fight cancer.
Not a Cure, But a Potential Bridge
It’s crucial to emphasize that ONCOS-102 is not a cure for prostate cancer. The study demonstrates a potential to *delay* the need for more aggressive treatments, offering men more time on active surveillance and potentially avoiding the immediate side effects of hormone therapy. Further research is needed to determine the long-term benefits of this approach and to identify which patients are most likely to respond.
“This is a promising step forward, but it’s still early days,” says Dr. Palapattu. “We need larger, randomized controlled trials to confirm these findings and to understand how best to integrate this treatment into the overall management of prostate cancer.” A Phase 3 trial is currently being planned to further evaluate the efficacy and safety of ONCOS-102.
Implications for Active Surveillance
Active surveillance is becoming an increasingly common approach for managing early-stage, low-risk prostate cancer. However, a major concern with active surveillance is the potential for disease progression, which may necessitate a switch to more aggressive treatments. ONCOS-102 offers a potential tool to extend the duration of active surveillance, allowing more men to avoid or delay the need for hormone therapy or surgery.
The findings also highlight the growing recognition of the importance of the tumor microenvironment in cancer development and progression. Targeting the microenvironment, rather than the cancer cells themselves, is emerging as a promising strategy for treating a variety of cancers. This approach may be particularly effective in cancers that are resistant to traditional therapies.
For men considering active surveillance for prostate cancer, it’s vital to discuss the potential benefits and risks with their healthcare provider. The availability of new treatments like ONCOS-102 may influence treatment decisions and offer new hope for managing this common disease.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
The next step in evaluating ONCOS-102 will be the results of the planned Phase 3 clinical trial, which will provide more definitive evidence of its efficacy and safety. Researchers are also exploring the potential of combining ONCOS-102 with other therapies, such as immunotherapy, to further enhance its effectiveness. Share your thoughts on this promising research in the comments below, and please share this article with anyone who may discover it helpful.
Worth a look
